Abstract
Immune checkpoint inhibitors (ICIs) are a key component of treating advanced cancer patients, principally antibodies against CTLA-4 and PD-1 or PD-L1.......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
